Raw Materials for Cell and Gene Therapy Summit on October 26-28, 2026 in San Diego, United States

Cell and gene therapies are advancing into late-stage development and commercialization, where raw materials have become a critical determinant of whether programs succeed or fail. Small inconsistencies that once went unnoticed are now triggering regulatory scrutiny, inflating cost of goods, and causing delays that put timelines and patient access at risk.

Following the sunshine to San Diego, the 3rd Raw Materials for Cell and Gene Therapy Summit is the only dedicated forum designed to help you take control of this risk. Through technical case studies and cross-functional discussion, you will uncover practical, phase-appropriate strategies to manage variability, strengthen supplier qualification, and build raw material frameworks that scale confidently from early development through to commercial manufacturing.

By joining leading experts across quality, MSAT, supply chain, and process development, you will engage in face-to-face discussions on how peers are defining material specifications, managing lot-to-lot variability, and making critical qualification decisions under real development pressure.

This collaborative environment enables open, candid exchange that simply cannot be replicated through reports or virtual formats. Leave with the clarity to make better decisions on raw material selection and supplier qualification, the confidence to defend them, and the relationships needed to accelerate your path to reliable, cost-effective, and scalable cell and gene therapy manufacturing.

URLs:
Tickets: https://go.evvnt.com/3703859-2?pid=10008
Brochure: https://go.evvnt.com/3703859-3?pid=10008

Time: 9:00 AM - 3:30 PM

Venue Details: The Westgate Hotel, 1055 Second Avenue, San Diego, California, 92101, United States

Category: Conferences | Science, Health and Medicine | Pharmaceuticals

Prices:

Drug Developer Pricing - 3 Day Pass (Workshop Day + Conference): USD 4397.00,

Drug Developer Pricing - 2 Day Pass (Conference Only): USD 3099.00,

Academic Pricing - 3 Day Pass (Workshop Day + Conference): USD 3797.00,

Academic Pricing - 2 Day Pass (Conference Only): USD 2699.00,

Service Provider Pricing - 3 Day Pass (Workshop Day + Conference): USD 5297.00,

Service Provider Pricing - 2 Day Pass (Conference Only): USD 3799.00

Speakers: Alison Burkart, Director, Analytical Development, Astellas Pharma, Lili Belcastro, Associate Director, Raw Materials, Drug Product Process Development, Bristol Myers Squibb, Kien Khuu-Duong, Associate Director, Bristol Myers Squibb, Lindsay Pierle, Senior Manager, Lifecycle Management MSAT, Johnson and Johnson, Donald Powers, Senior Director, Advanced Therapies Supply Chain, Johnson and Johnson, Arthur Zeng, Principal Scientist II, Johnson and Johnson , Shawn Wang, Director, Head of Material Development, Kite Pharma Inc, Aditya Dandekar, Associate Director, Cabaletta Bio, Basak Clements, Independent Raw Materials Expert and USP CGT Expert Committee Member, biomatria, Ben Clarke, Senior Scientist, Global Biologics, U.S. Pharmacopeia, Benjamin Cho, Technical Development Scientist II, Genentech, Daniel Anaya, Associate Director, MS and T, Ray Therapeutics, James Adams, Chief Technical Officer, Tr1x therapeutics, Kim Raineri, Chief Technology Officer, Aspen Neuroscience, Kok Seong Lim, Independent Expert, Lauren Fong, Associate Director, Raw Material Quality, Fate Therapeutics, Mayo Pujols, Chief Technology Officer, Kyverna Therapeutics